PDS Biotechnology Corporation has announced the presentation of preliminary results from a National Cancer Institute $(NCI)$-led Phase 2 study of its investigational Interleukin-12 (IL-12) tumor-targeted immunocytokine, PDS01ADC, in patients with third-line metastatic castration-resistant prostate cancer. The results, which showed a median progression-free survival $(PFS)$ of 9.6 months, were presented at the American Association of Cancer Research (AACR) Special Conference on Innovations in Prostate Cancer held in Boston, MA, from January 20-22, 2026. PDS01ADC is an IL-12 antibody drug conjugate designed for targeted delivery of IL-12 into the tumor microenvironment to enhance immune response against cancer cells.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PDS Biotechnology Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9643904-en) on January 28, 2026, and is solely responsible for the information contained therein.